A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT - Patil, Shivaprasad Gangadhar; Linge, Annett; Hiepe, Hannah; Grosser, Marianne; Lohaus, Fabian; Gudziol, Volker; Kemper, Max; Nowak, Alexander; Haim, Dominik; Tinhofer, Inge; Budach, Volker; Guberina, Maja; et al. (Cancers, 2022)
Gesehen am 08.08.2022